Clinical Trials Logo

Ticagrelor clinical trials

View clinical trials related to Ticagrelor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05210595 Recruiting - Clinical trials for Acute Myocardial Infarction

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for clinical practice in Korea is unclear. Therefore, the investigators aim to evaluate efficacy and safety of low dose of ticagrelor in Acute Myocardial Infarction (AMI) undergoing percutaneous coronary intervention(PCI).

NCT ID: NCT03161002 Recruiting - Pharmacokinetics Clinical Trials

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

Start date: May 31, 2017
Phase:
Study type: Observational

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Ticagrelor is a new-type receptor antagonist of P2Y12 and it is not affected by the influence of CYP2C19 polymorphism. With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of ticagrelor in the antiplatelet efficacy and safety, through the pharmacogenomics research. The aim of this study is to determine the polymorphism of drug metabolizing enzymes, drug transporters and drug target genes in Chinese population. By detecting the gene polymorphism, we intend to study the pharmacokinetic/ pharmacodynamics/ pharmacogenomics (PK-PD-PG) correlation of ticagrelor and provide scientific basis for accurate medication guide for people to use ticagrelor.

NCT ID: NCT03005704 Recruiting - Aspirin Clinical Trials

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

REVSTARTS
Start date: January 2017
Phase: N/A
Study type: Interventional

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.